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ABSTRACT
With rapid advances in our understanding of cancer, there 
is an expanding number of potential novel combination 
therapies, including novel–novel combinations. Identifying 
which combinations are appropriate and in which 
subpopulations are among the most difficult questions in 
medical research. We conducted a Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses 
(PRISMA)- guided systematic review of trials of novel–novel 
combination therapies involving immunotherapies or 
molecular targeted therapies in advanced solid tumors. 
A MEDLINE search was conducted using a modified 
Cochrane Highly Sensitive Search Strategy for published 
clinical trials between July 1, 2017, and June 30, 2020, 
in the top- ranked medical and oncology journals. Trials 
were evaluated according to a criterion adapted from 
previously published Food and Drug Administration 
guidance and other key considerations in designing trials 
of combinations. This included the presence of a strong 
biological rationale, the use of a new established or 
emerging predictive biomarker prospectively incorporated 
into the clinical trial design, appropriate comparator arms 
of monotherapy or supportive external data sources and 
a primary endpoint demonstrating a clinically meaningful 
benefit. Of 32 identified trials, there were 11 (34%) trials 
of the novel–novel combination of anti- programmed 
death 1 (PD-1)/programmed death ligand 1 (PD- L1) and 
anti- cytotoxic T lymphocyte- associated antigen-4 (CTLA-
4) therapy, and 10 (31%) trials of anti- PD-1/PD- L1 and 
anti- vascular endothelial growth factor (VEGF) combination 
therapy. 20 (62.5%) trials were phase II trials, while 12 
(37.5%) were phase III trials. Most (72%) trials lacked 
significant preclinical evidence supporting the development 
of the combination in the given indication. A majority of 
trials (69%) were conducted in biomarker unselected 
populations or used pre- existing biomarkers within the 
given indication for patient selection. Most studies (66%) 
were considered to have appropriate comparator arms or 
had supportive external data sources such as prior studies 
of monotherapy. All studies were evaluated as selecting 
a clinically meaningful primary endpoint. In conclusion, 
designing trials to evaluate novel–novel combination 
therapies presents numerous challenges to demonstrate 
efficacy in a comprehensive manner. A greater 
understanding of biological rationale for combinations 
and incorporating predictive biomarkers may improve 
effective evaluation of combination therapies. Innovative 
statistical methods and increasing use of external data to 
support combination approaches are potential strategies 
that may improve the efficiency of trial design. Designing 
trials to evaluate novel–novel combination therapies 
presents numerous challenges to demonstrate efficacy 
in a comprehensive manner. A greater understanding of 
biological rationale for combinations and incorporating 
predictive biomarkers may improve effective evaluation of 
combination therapies. Innovative statistical methods and 
increasing use of external data to support combination 
approaches are potential strategies that may improve the 
efficiency of trial design.
INTRODUCTION
With rapid advances in our understanding 
of cancer genomics and immunobiology, an 
expanding number of novel therapies are 
being evaluated in clinical trials.1 As a conse-
quence, there is an exponentially increasing 
number of mathematically possible drug 
combinations,2 including novel–novel combi-
nations, in which two or more drugs are 
investigational and are not yet approved stan-
dards of care. Concordantly, there has been 
an increase in the number of clinical trials 
evaluating combination therapies.3 The use 
of combination therapies to improve effi-
cacy has traditionally been a central tenet 
of medical oncology ever since the initial 
use of combination chemotherapy regimens 
in hematological malignancies and breast 
cancer.4 The underlying rationale is anchored 
in the synergistic or additive effects of drugs 
with differing and potentially complementary 
mechanisms of action to increase the likeli-
hood of response, forestall or overcome resis-
tance and minimize overlapping toxicities. 
However, patient- to- patient variability and 
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the independent action of drugs may also confer benefit 
for combination therapies without additive or synergistic 
interactions.5
Multiarm, ‘pick- the- winner’ or factorial trial designs 
may often be used to evaluate more than one novel treat-
ment individually and in combination in a single trial.6 
However, it may be impractical to conduct such trials 
due to finite resources, particularly with an increasing 
number of novel therapies and potential combinations. 
Identifying which combinations are appropriate in which 
patient subpopulations are among the most difficult ques-
tions in medical research. Garnering regulatory approval 
requires demonstrating that each component of a combi-
nation contributes to its benefit. This creates numerous 
challenges for clinicians, industry and regulatory bodies 
alike in designing, conducting and interpreting trials 
of novel–novel combination therapies. Therefore, the 
rational, efficient and effective evaluation of novel–novel 
drug combinations is crucial. Regulatory agencies, such 
as the US Food and Drug Administration (FDA), have 
recognized these challenges and have released formal 
guidance for trial sponsors.7 Nevertheless, a fine balance 
between the level of evidence required to obtain regula-
tory approval of a novel–novel combination versus the 
practicality of conducting such trials is needed. Further-
more, as the drug development landscape in oncology 
continues to evolve, such as the advent of immunothera-
peutic strategies, capabilities to adapt clinical trial design 
remain crucial.8
We sought to conduct a focused systematic review of clin-
ical trials of novel–novel combination therapies involving 
immunotherapies or molecular targeted therapies in 
advanced solid tumors in order to identify opportunities 
to improve paradigms for the drug development pathway 
and clinical trial evaluation of the efficacy of rational 
combination therapies. Selected studies were evaluated 
and assessed according to a set of criteria adapted from 
the aforementioned FDA guidance and other key consid-
erations in designing trials of novel–novel combination 
therapies. This included the underlying biological ratio-
nale for the combination, the incorporation of an estab-
lished or emerging predictive biomarker, and the clinical 




The search strategy was conducted in MEDLINE 
according to a modified Cochrane Highly Sensitive 
Search Strategy to identify published clinical trials that 
evaluated novel combination therapies in advanced solid 
tumors. In order to maintain contemporary relevance 
and focus on the most innovative/promising agents, our 
search covered the time period from July 1, 2017, to June 
30, 2020, and was restricted to articles published in eight 
selected high- tier peer- reviewed journals (New England 
Journal of Medicine, Lancet, Journal of the American Medical 
Association, Lancet Oncology, Journal of Clinical Oncology, 
Cancer Discovery, JAMA Oncology, and Annals of Oncology). 
These journals were selected as the top- ranked general 
medical or general oncology journals by impact factor 
that publish oncology clinical trials according to the 
Journal Citation Reports 2019.
Study selection
A priori inclusion criteria were established. To be eligible 
for inclusion, studies had to be primary research arti-
cles reporting the outcomes of a phase II or III clinical 
trial evaluating novel–novel combination therapy with 
programmed death 1 (PD-1)/programmed death ligand 
1 (PD- L1) or cytotoxic T lymphocyte- associated antigen-4 
(CTLA-4) immune checkpoint targeting agents or molec-
ularly targeted agents. Novel–novel combination therapy 
was defined as two or more investigational drugs, of which 
none were approved or recommended by treatment 
guidelines for the given indication. Exclusion criteria 
included pediatric studies (subjects<18 years of age), 
observational studies, meta- analyses, publications using 
pooled data from two or more trials, dose finding or phase 
I trials, early stage or locally advanced solid tumor studies, 
and hematological studies. In cases of updated analyses 
after initial study publication, studies were included in 
this analysis only if prespecified additional analysis for 
mature data of primary endpoints was being reported. 
Board- certified or equivalent oncologists (ACT and MK) 
reviewed the articles for final eligibility, and disagreement 
was resolved by discussion and consensus.
Data extraction
Data extracted for each study included (1) study name/
clinical trial ID; (2) journal; (3) authors; (4) trial sponsor; 
(5) tumor type and study population (newly diagnosed 
vs recurrent); (6) drugs studied; (7) treatment arms; 
(8) trial phase; (9) treatment regimens; (10) Common 
Terminology Criteria for Adverse Events version used; 
(11) biomarker selection criteria; (12) trial endpoints; 
(13) response data including objective response rate 
(ORR); (14) survival data including progression- free 
survival (PFS) and overall survival (OS); (15) adverse 
event data, including number of total and severe adverse 
events and mortality; (16) FDA approval for the combina-
tion therapy as of September 2020.
Study evaluation and statistical analysis
The trial design of each study was evaluated according 
to a set of criteria adapted from the criteria outlined by 
the FDA in their guidance on the development of novel 
combination therapies.7 As this review consisted only of 
studies involving patients with advanced cancer, it was 
accepted that all studies fulfilled the first FDA criteria, in 
that studies were evaluating a combination treatment for 
a serious disease or condition. Further general criteria in 
the FDA guidance included (1) a strong biological ratio-
nale for use of the combination and (2) the combina-
tion may provide a significant therapeutic advance over 
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available therapy and is superior to the individual agents. 
In addition, factors which contribute to the efficiency of 
trial design and subsequent clinical impact, such as the 
use of external data sources and clinically meaningful 
primary endpoints, were also evaluated.
Trial designs were assessed according to the following 
criteria:
1. A strong biological rationale, defined as any published 
in vitro or in vivo preclinical data demonstrating ac-
tivity specifically for the combination therapy with 
class- specific agents over the individual agents alone 
in the given indication. The presence of a biological 
rationale was considered ‘limited’ if published preclin-
ical data were conducted only in a single experimental 
model system.
2. Use of a new established or emerging predictive bio-
marker prospectively incorporated into the clinical 
trial design to define eligible patients for the combi-
nation therapy and for which there are no approved 
or recommended therapeutic options for the given 
biomarker.
3. Appropriate comparator arms where applicable, allow-
ing for an evaluation of the efficacy and safety of the 
individual agents alone, or supportive external data 
sources such as prior studies of monotherapy.
4. Primary endpoint which demonstrates a clinically 
meaningful benefit in the given indication and ac-
cording to the phase of trial, such as ORR, PFS and/
or OS.
RESULTS
Study selection and characteristics
We identified 160 potentially eligible studies. After full- 
text review and applying the selection criteria, 32 studies 
were included in the final analysis (figure 1). The char-
acteristics of the studies are listed in table 1. Studies were 
broadly classified based on the drug–target combination 
for further in- depth analysis according to the evaluation 
criteria (see online supplemental appendix for additional 
results).
Inhibition of PD-1/PD-L1 and CTLA-4 combination therapy
There were 11 trials of the novel–novel combination of 
anti- PD-1/PD- L1 and anti- CTLA-4 therapy, as shown 
in figure 2, table 2 and online supplemental appendix, 
including six (55%) phase II and five (45%) phase III 
trials. There were four studies conducted in non- small 
cell lung cancer (NSCLC), with a range of other tumor 
types in the remaining studies (figure 2).
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Rationale for combinations
We first assessed for the presence of a strong biolog-
ical rationale for the combination approach, according 
to preclinical data supporting superior efficacy of the 
combination compared with the individual agents alone, 
in the given indication. The combination of nivolumab 
and ipilimumab was first approved in unresectable or 
metastatic melanoma in 2015, while there is currently no 
approved indication for the combination of durvalumab 
and tremelimumab. Preclinical models in melanoma 
demonstrated the enhanced antitumor activity for 
combination checkpoint blockade,9 and development 
of the combination was also supported by synergistic 
activity observed in murine colorectal and ovarian tumor 
models.10 11 Anti- CTLA-4 therapy impacts the lymphoid 
compartment, resulting in an increase in the number as 
well as breadth of specificity of tumor antigen reactive 
T cells, whereas anti- PD-1 impacts the immunosuppres-
sion within the tumor microenvironment. Clinical activity 
was subsequently seen in a phase I trial of nivolumab 
and ipilimumab in patients with advanced melanoma.12 
As a result, trials of combination checkpoint blockade 
were evaluated in numerous other cancers. Of the 11 
trials investigating inhibition of PD-1/PD- L1 and CTLA-4 
combination therapy included in this review, there was a 
distinct absence of a strong biological rationale in most 
studied indications, with limited in vitro or in vivo data 
supporting the combination, although in many cases 
Table 1 Study characteristics
Characteristics (n=32) n (%)
Trial phase
  II 20 (62.5)
  III 12 (37.5)
Trial sponsor
  Academic 10 (31)
  Industry 22 (69)
Tumor type
  Breast 1 (3)
  Colorectal 4 (13)
  Endometrial 1 (3)
  HCC 1 (3)
  HNSCC 1 (3)
  Melanoma 1 (3)
  Mesothelioma 1 (3)
  Multiple, including basket 2 (6)
  NSCLC 5 (16)
  Ovarian 2 (6)
  Pancreatic 1 (3)
  RCC 7 (22)
  Salivary 1 (3)
  Sarcoma 3 (9)
  Thyroid 1 (3)
Journal
  Annals of Oncology
  
4 (13)
  Cancer Discovery 0 (0)
  JAMA 0 (0)
  JAMA Oncology 7 (22)
  Journal of Clinical Oncology 5 (16)
  Lancet 1 (3)
  Lancet Oncology 8 (25)




  Immunotherapy 13 (41)
  Targeted therapy 8 (25)




  PD-1/PD- L1+CTLA-4 11 (34)
  PD-1/PD- L1+VEGF 10 (31)
  BRAF+MEK (±EGFR) 4 (13)
  HER2 2 (6)
  Other* 5 (16)
Biomarker selection
  Selected 15 (47)
Continued
Characteristics (n=32) n (%)
  Unselected 17 (53)
Primary endpoint
  Phase II trials (n=36)
  ORR 15 (75)
  PFS 3 (15)
  OS 1 (5)
  DCR 1 (5)
  Phase III trials (n=12)
  PFS 2 (17)
  OS 3 (25)
  PFS and OS 6 (50)
*Chemotherapy+VEGF, chemotherapy+PARP, PD-1+HPV16 
vaccine, PD-1+oncolytic virus, PD- L1+MEK.
CTLA-4, cytotoxic T lymphocyte- associated antigen-4; DCR, 
disease control rate; EGFR, epidermal growth factor receptor; 
HCC, hepatocellular carcinoma; HER2, human epidermal 
growth factor receptor 2; HNSCC, head and neck squamous 
cell carcinoma; JAMA, The Journal of the American Medical 
Association; MEK, mitogen- activated protein kinase kinase; 
NSCLC, non- small cell lung cancer; ORR, objective response rate; 
OS, overall survival; PARP, poly(ADP- ribose) polymerase; PD-1, 
programmed death 1 
; PD- L1, programmed death ligand 1 
; PFS, progression- free survival; RCC, renal cell carcinoma; VEGF, 
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there were preliminary signs of efficacy in early- phase 
trials, including phase I trials, emphasizing the need for 
better preclinical models to select rational combination 
immunotherapy approaches.13
Utility of biomarkers
Next, we assessed the incorporation of a newly established 
or emerging predictive biomarker into the trial design 
that may suggest efficacy of the combination superior to 
monotherapy. Of the 11 trials, 6 (55%) were conducted in 
unselected patient populations. Four (44%) trials selected 
patients based on PD- L1 status, a previously established 
but somewhat controversial biomarker to select patients 
for anti- PD-1/PD- L1 monotherapy. Only one (9%) trial 
incorporated a new established or emerging biomarker, 
with the CheckMate 227 trial including a coprimary 
endpoint of PFS in patients with high tumor mutation 
burden (TMB) for nivolumab plus ipilimumab versus 
chemotherapy.14
Comparator arms
The use of appropriate comparator arms that would allow 
for the comparison of the efficacy and safety of the indi-
vidual agents alone versus the combination was also crit-
ically examined. This was evaluated in the context of the 
presence or absence of supportive external data sources, 
such as prior studies of monotherapy. Of the phase III 
trials, one trial was conducted in first- line renal cell carci-
noma (RCC), with the remaining trials conducted in 
NSCLC. CheckMate 214 evaluated nivolumab plus ipili-
mumab versus sunitinib as first- line therapy in advanced 
RCC.15 There was prior monotherapy data for ipilim-
umab in a phase II trial that allowed pretreated and treat-
ment naïve patients.16 Nivolumab monotherapy, already 
approved in the treatment resistant setting,17 had also 
been evaluated in treatment- naïve patients in a multi-
cohort phase Ib expansion study.18 CheckMate 227 was 
an open- label phase III randomized trial in untreated 
advanced NSCLC.14 19 The trial was designed to test 
multiple nivolumab- based regimens in different patient 
populations. Nivolumab monotherapy had been previ-
ously evaluated in treatment- naïve advanced NSCLC in 
the phase III CheckMate 026 study in patients with PD- L1 
expression of 5% or more,20 while ipilimumab mono-
therapy had been evaluated in a previous phase II trial.21 
Durvalumab plus tremelimumab was evaluated in two 
phase III trials for NSCLC, with the MYSTIC trial22 as first- 
line therapy and the ARCTIC trial23 as third- line or later 
line therapy. Durvalumab monotherapy had been investi-
gated in the treatment- refractory setting in NSCLC,24 but 
neither durvalumab or tremelimumab monotherapy had 
been previously evaluated in the first- line setting.
Overall, the phase II and III trials of combination anti- 
PD-1/PD- L1 and anti- CTLA-4 therapy were appropriately 
designed with comparator arms of either individual agent 
alone and where there were no prior studies in the given 
indication.
Primary endpoints
The primary endpoints of the selected studies were also 
evaluated. In general, the phase II studies used ORR or 
DCR, while the phase III studies used PFS and/or OS. 
The primary endpoints were assessed overall as appro-
priate and clinically meaningful in all studies.
Inhibition of PD-1/PD-L1 and VEGF combination therapy
There were 10 trials of the novel–novel combination of 
anti- PD-1/PD- L1 and anti- vascular endothelial growth 
factor (VEGF) therapy, as shown in figure 3, online 
supplemental table 1 and online supplemental appendix.
Rationale for combinations
The combination of antiangiogenic therapy and immune 
checkpoint inhibitor therapy is based on evidence 
demonstrating that aberrant angiogenesis is a hallmark 
of many solid tumors, resulting in immune evasion.25 
Therefore, normalization of abnormal tumor vascula-
ture with antiangiogenic therapy may improve immune 
effector cell function by decreasing hypoxia, acidosis and 
nutrient deprivation and may increase the infiltration 
of immune effector cells into the tumor microenviron-
ment in order to enhance the efficacy of immunotherapy. 
VEGF also has pleotropic immunosuppressive effects 
including impairment of dendritic cell function, as well 
as mobilization of immunosuppressive cells such as tumor 
associated macrophages, regulatory T cells, and myeloid- 
derived suppressor cells.26 Consequently, this has led to 
a proliferation of studies of novel–novel combinations 
of therapeutics from these two classes. Improved effi-
cacy with combination inhibition of VEGF and immune 
checkpoint blockade has been shown in animal models 
for melanoma,27 colorectal cancer,28 breast cancer and 
Figure 2 Characteristics of combination anti- PD-1/PD- L1 and anti- CTLA-4 therapy trials. (A) Combination therapy regimen, 
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pancreatic neuroendocrine tumors.29 Specifically, lenva-
tinib plus anti- PD-1 therapy has also been evaluated 
in murine hepatocellular, colorectal and melanoma 
models.30 31 However, preclinical data demonstrating the 
efficacy of other specific drug combinations are sparse. 
For example, the combination of axitinib plus avelumab 
in RCC had not been published in preclinical models, 
and the rationale for the combination as first- line therapy 
was based on the toxicity profile for axitinib, with lower 
hepatotoxicity compared with sunitinib.32 There were 
also no preclinical data published for the remaining 
combination therapies in the given studied indications.
Utility of biomarkers
Of the 10 trials evaluating combination anti- PD-1/PD- L1 
and anti- VEGF therapy, a majority (80%) were conducted 
in biomarker unselected populations of patients. The 
two (20%) trials, which included biomarker selection 
criteria, selected patients on the basis of PD- L1 IHC for 
avelumab33 and atezolizumab,34 respectively, in advanced 
RCC. PD- L1 IHC had not been previously established as 
a biomarker for patient selection for anti- PD-1/PD- L1 
therapy in advanced RCC and therefore represented a 
new predictive biomarker in this patient population. No 
robust biomarkers for anti- VEGF therapy have been iden-
tified, and consequently, no trial attempted to select a 
biomarker for this class of agents.
Comparator arms
Overall, the phase II trials of combination anti- PD-1/
PD- L1 and VEGF therapy were appropriately designed 
with comparator arms of either individual agent alone 
and where there were no prior studies in the given indica-
tion. Two phase III trials in patients with treatment- naïve 
metastatic RCC involved axitinib combinations. Axitinib 
monotherapy is approved in the second- line setting35 but 
had not been previously evaluated as first- line therapy.
Primary endpoints
The primary endpoint in five of the six phase II trials 
was ORR, with the remaining trial of pembrolizumab 
plus axitinib in metastatic sarcoma using PFS rate at 3 
months as the primary endpoint. Coprimary endpoints 
of PFS and OS were used in the four phase III trials of 
combination anti- PD-1/PD- L1 and anti- VEGF therapy. 
Overall, these endpoints were considered appropriate 
and clinically meaningful. It should be borne in mind 
that in tumors of the central nervous system, both pseu-
doprogression and pseudoresponse have been identified 
as limiting characteristics of immune checkpoint inhib-
itors and antiangiogenic inhibitors, respectively, and in 
certain extracranial settings, concern regarding post- 
treatment peritumoral inflammatory changes (‘pseudo-
progression’) following checkpoint inhibition has been 
described. These could limit the validity of ORR as an 
endpoint in such studies.
Inhibition of BRAF and MEK combination therapy
There were four trials of the novel–novel combination of 
BRAF and mitogen- activated protein kinase kinase (MEK) 
inhibitor therapy, as shown in online supplemental table 
2 and online supplemental appendix. In addition, the 
BEACON CRC trial evaluated epidermal growth factor 
receptor (EGFR) inhibitor therapy in combination with 
BRAF and MEK inhibition.36
Rationale for combinations
In BRAF- mutated melanoma, the combination of BRAF 
and MEK- pathway inhibition had initially established clin-
ical efficacy and tolerability compared with BRAF- inhibitor 
monotherapy with two combinations (dabrafenib plus 
trametinib, and vemurafenib plus cobimetinib).37 38 
BRAF and MEK inhibitor combinations were originally 
developed based on preclinical data demonstrating that 
the combination could improve efficacy and delay the 
emergence of resistance.39 40 Reactivation of the MAPK 
pathway was a commonly reported mechanism of resis-
tance to BRAF- inhibitor monotherapy.41 42 The combi-
nation of encorafenib and binimetinib was subsequently 
evaluated due to the increased potency of encorafenib 
compared with dabrafenib and vemurafenib, related to 
a greater dissociation half- life and improved pharmaco-
dynamics.43 Furthermore, the combination with binime-
tinib, which ameliorated the toxicity of encorafenib 
monotherapy, allowed for high doses of encorafenib in 
the combination treatment.43
The rationale for the inhibition of BRAF, MEK and 
EGFR in BRAF V600E mutated colorectal cancer was 
developed after extensive preclinical investigations char-
acterizing these pathways. Rapid feedback activation 
through EGFR after BRAF inhibition alone explained the 
poor efficacy of BRAF monotherapy and led to the devel-
opment of BRAF plus EGFR inhibitor combinations.44 45 
Subsequently, the combination of BRAF and MEK inhibi-
tion to improve efficacy compared with BRAF plus EGFR 
inhibition was also demonstrated preclinically.46 47
Figure 3 Characteristics of combination anti- PD-1/PD- L1 and anti- VEGF therapy trials. (A) Combination therapy regimen, (B) 
tumor type, and (C) trial phase. HCC, hepatocellular carcinoma; RCC, renal cell carcinoma.
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Utility of biomarkers
All four combination trials of BRAF plus MEK inhibi-
tion selected patients based on the presence of a BRAF 
mutation. For advanced melanoma, there were already 
approved therapies for patients harboring BRAF muta-
tions. In the remaining tumor types, however, the combi-
nation therapies represented a new genotype- directed 
therapeutic option.
Comparator arms and primary endpoints
COLUMBUS was a three- arm, randomized phase III 
study evaluating combination encorafenib (450 mg daily 
dose) plus binimetinib versus encorafenib monotherapy 
(300 mg daily dose) versus vemurafenib monotherapy.48 
Binimetinib monotherapy had previously been investi-
gated in a phase II study for patients with NRAS or BRAF- 
mutated melanoma.49 BEACON CRC (Binimetinib, 
Encorafenib, and Cetuximab Combined to Treat BRAF- 
Mutant Colorectal Cancer) was also a three- arm, random-
ized phase III study, with study arms consisting of triplet 
therapy (encorafenib, binimetinib and cetuximab), 
doublet therapy (encorafenib and cetuximab) or inves-
tigator’s choice of cetuximab plus irinotecan or cetux-
imab plus FOLFIRI (control group).36 There had been 
no prior trials of encorafenib, binimetinib or cetuximab 
monotherapy in patients with advanced BRAF V600E 
mutated colorectal cancer. Cetuximab monotherapy had 
previously been studied in unselected patients with meta-
static colorectal cancer.50 Retrospective analyses, however, 
suggested responses to cetuximab may be lower in patients 
with BRAF mutations.51 Additionally, vemurafenib mono-
therapy had been investigated in BRAF V600E mutated 
colorectal cancer in a small phase II trial and a basket 
trial.52 53 There was no meaningful clinical activity for 
vemurafenib monotherapy, with only one response out of 
31 patients across the two trials. The primary endpoints in 
COLUMBUS and BEACON CRC were both considered 
clinically meaningful.
Inhibition of HER2 combination therapy
There were two studies reporting the novel–novel combi-
nation of human epidermal growth factor receptor 2 
(HER2) inhibitor therapy with trastuzumab and pertu-
zumab, as shown in online supplemental table 3 and online 
supplemental appendix. Both studies were reports from 
the MyPathway basket trial for patients with colorectal 
cancer54 and salivary gland cancers,55 respectively.
Rationale for combinations
In colorectal cancer, pre- clinical data from HER2- 
amplified colorectal tumor grafts or xenografts, had 
demonstrated limited activity of single agent HER2 
targeted therapy with trastuzumab, pertuzumab or lapa-
tinib.56 57 Anti- tumor activity however, was increased with 
combination HER2 targeting regimens, although with 
trastuzumab plus lapatinib or pertuzumab plus lapa-
tinib. The complementary mechanisms of action of tras-
tuzumab and pertuzumab, and demonstrated efficacy 
in breast cancer,58 provided a strong rationale for this 
combination in HER2- amplified colorectal cancer.
Utility of biomarkers
As HER2 targeted therapies had not been approved in 
either tumor type, both studies were assessed as incorpo-
rating a new established or emerging biomarker.
Comparator arms and primary endpoints
As a phase IIa multiple basket trial of various targeted 
therapies in advanced solid tumors, ORR was considered 
an appropriate and clinically meaningful endpoint for 
the MyPathway trial. Understandably, as a basket trial, 
comparator arms of either trastuzumab or pertuzumab 
monotherapy were not included in this trial.
Other combination therapies
There were five trials evaluating other novel–novel 
combination therapies, including chemotherapy plus 
VEGF inhibitor therapy, chemotherapy plus poly(ADP- 
ribose) polymerase (PARP) inhibitor therapy, anti- PD-1 
plus HPV16 vaccine therapy, anti- PD-1 plus an oncolytic 
virus therapy, and anti- PD- L1 plus MEK inhibitor therapy 
(online supplemental appendix and online supplemental 
table 4).
COTEZO IMblaze 370 was a three- arm randomized 
phase III study of atezolizumab plus cobimetinib versus 
atezolizumab monotherapy versus regorafenib in patients 
with previously treated metastatic colorectal cancer.59 In 
the initial phase I trial of cobimetinib monotherapy, there 
were 41 patients with metastatic colorectal cancer, but no 
responses were seen.60 The combination of anti- PD- L1 
and MEK inhibitor in colorectal cancer was developed on 
the basis of preclinical data, suggesting MEK inhibition 
could affect the immune contexture in the tumor micro-
environment.61 Cobimetinib had been shown to increase 
T- cell infiltration into tumors and downregulate immu-
nosuppressive cytokines and receptors.62 Combination 
therapy of cobimetininb with anti- PD- L1 inhibition also 
resulted in synergistic and durable tumor regression in 
mice models.62
BROCADE was a three- arm phase II trial for patients 
with BRCA1/2- mutated recurrent or metastatic breast 
cancer.63 Patients were randomized to receive veliparib 
plus carboplatin/paclitaxel or veliparib plus temozolo-
mide or carboplatin/paclitaxel. The primary endpoint 
was PFS comparing both veliparib containing arms with 
chemotherapy alone. Veliparib plus temozolomide was 
considered the novel–novel combination for this review. 
Veliparib monotherapy had been evaluated in a single- arm 
phase II trial for patients with germline BRCA1/2 asso-
ciated metastatic breast cancer,64 while temozolomide 
monotherapy had previously shown a lack of activity in an 
unselected population of patients with metastatic breast 
cancer.65 The rationale for the combination of temozolo-
mide and veliparib was from preclinical breast cancer 
models which demonstrated synergistic activity for the 
combination.66 67 At the time the study was developed, 
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there were no targeted therapies approved for patients 
BRCA1/2- mutated breast cancers.68
Overall evaluation of novel–novel combination therapies in 
oncology
The overall assessment and evaluation of trial designs of 
novel–novel combination therapies according to the four 
criteria are shown in figure 4.
Discussion
With an expanding number of novel therapies in clin-
ical development and possible drug combinations, the 
fundamental challenge remains to evaluate rational 
combinations efficiently and effectively. In particular, a 
mechanistic understanding of the contribution of each 
drug to the treatment effect is needed, both from a scien-
tific and regulatory perspective.69 Based on a systematic 
review of the top general medical and oncology journals 
over the past 3 years, we identified 32 recently published 
trials evaluating novel–novel combinations and evaluated 
each trial according to criteria adapted from FDA guid-
ance on the development of novel combination therapies 
(box 1).
First, we assessed the strength of the biological rationale 
according to the presence of published preclinical data. 
Most trials (72%) lacked significant preclinical evidence 
supporting the development of the combination in the 
given indication. This was particularly evident in studies 
evaluating combination immune checkpoint blockade, 
for which there were only two studies with limited preclin-
ical data in colorectal and ovarian cancers. This could, in 
part, be attributed to difficulties in developing preclinical 
animal models for immunotherapy, due to the inability of 
immunocompetent animal models to fully recapitulate 
the human immune system.70 Phase I studies were also 
excluded from our analysis, for which preclinical data may 
be especially relevant in the initial decision to evaluate a 
combination. Notably, however, significant clinical efficacy 
in tumor types such as NSCLC14 19 and RCC15 has been 
seen, despite the lack of supportive preclinical data. For 
some of these tumors (such as RCC), evidence of single 
agent activity or early efficacy in phase I trials served as 
the rationale for subsequent combination phase II and 
III studies. Coupled with the initial outcomes of trials in 
melanoma,12 this has resulted in a rapid increase in the 
number of combination immunotherapy trials.3 Neverthe-
less, the value of numerous trials with overlap and duplica-
tion in the combination partner targets, being conducted 
in unselected patients can be questioned,3 particularly in 
cancers for which single- agent immunotherapy has no 
activity. This observation highlights the importance of a 
greater understanding of tumor- specific immunity and the 
need to develop more effective biomarkers.71 Given the 
expanding number of potential combinations, rational 
selection of combinations based on mechanistic evidence 
and robust biological rationale is crucial.72 Additionally, 
for many trials in our review, preclinical data supporting 
the combination may have been demonstrated in other 
tumor types outside the given trial’s studied indication. 
Particularly for targeted therapies, there can be significant 
diversity across tumor types in the actionability of onco-
genic driver mutations.73 BRAF V600E mutations are a 
prominent example, with a spectrum of activity for combi-
nation BRAF and MEK inhibition across histologies.74 This 
diversity is also exemplified in colorectal cancer, with the 
role for combined BRAF plus EGFR inhibition demon-
strated elegantly in preclinical studies.44
Figure 4 Overall evaluation of novel–novel combination therapies of immune checkpoint inhibitors or molecular targeted 
agents in solid tumor oncology. (A) Strong biological rationale, (B) new biomarker, (C) comparator arms of monotherapy, and (D) 
clinically meaningful primary endpoint.
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We then evaluated the use of a newly established or 
emerging predictive biomarker incorporated into the 
clinical trial design. Similarly, we found that a majority 
of trials (69%) were conducted in biomarker unselected 
populations or used pre- existing biomarkers within 
the given indication for patient selection. No studies 
included separate novel predictive biomarkers for both 
novel agents. Biomarker- driven clinical trial designs and 
analysis plans present additional challenges and require 
careful consideration of the biomarkers’ performance 
and clinical utility.75 However, the use of biomarker- 
selected patients has the potential to both improve 
patient care and accelerate drug development with 
greater efficiency.76 CheckMate 227,14 which incorpo-
rated association of TMB with OS as a second coprimary 
endpoint after an amendment prior to the initial analysis, 
demonstrated the flexibility of a large phase III trial to 
adapt to the emerging science. The biomarker was also 
investigated as a subset of the overall trial population—
an important consideration in prospective biomarker- 
driven clinical trial design. Ultimately, the role for TMB 
as a predictive biomarker in NSCLC remains unclear.77 
Furthermore, despite tissue agnostic approval for TMB of 
≥10 as a biomarker for pembrolizumab,78 there remains 
controversy over its use with numerous biological and 
practical considerations across tumor types.79 80 This illus-
trates the difficulties in identifying predictive biomarkers, 
which may lag behind the development of novel therapeu-
tics.81 Dynamic biomarkers, which may change over time 
as tumors evolve, and the cost of developing biomarkers 
further complicate the development process. Neverthe-
less, particularly for immunotherapies, different agents 
may have pleiotropic effects on a variety of different cells 
and compartments where they are operational. There 
may also be heterogeneity in the relative contribution of 
Box 1 What is specifically learned about combinations of 
novel–novel agents?
Summary: We searched MEDLINE according to a modified Cochrane 
Highly Sensitive Search Strategy to identify published clinical trials 
that evaluated novel combination therapies in advanced solid tumors. 
Our search covered the period from July 1, 2017, to June 30, 2020. 
We restricted our search to articles published in eight selected peer- 
reviewed journals (New England Journal of Medicine, Lancet, Journal of 
the American Medical Association, Lancet Oncology, Journal of Clinical 
Oncology, Cancer Discovery, JAMA Oncology and Annals of Oncology). 
We identified 160 potentially eligible studies. After full- text review and 
applying the selection criteria, 32 studies were included in the final 
analysis (figure 1). Studies were broadly classified based on the drug–
target combination for further in- depth analysis. Below is a summary of 
the key messages and recommendation.
A. Key Messages
1. Combinations are the future of clinical trials and this is so in most 
diseases.
2. Identifying which combinations are appropriate and in which pa-
tient subpopulations are among the most difficult questions in 
medical research.
3. In 72% of the analyzed studies, there was no significant preclinical 
evidence supporting the development of the specific combination 
in the given indication. This was especially true in studies with 
combination immune checkpoint blockade. This, in part, may be 
due to difficulties in developing immunocompetent animal models 
to fully recapitulate the human immune system.
4. In 69% of the analyzed studies, trial populations were unselected 
and did not use pre- existing predictive biomarkers for the given 
indication for patient selection.
5. Sixty- six per cent of the trials analyzed had appropriate comparator 
arms or had supportive external data sources such as monother-
apy prior studies.
6. A greater understanding of the biological rationale for the combi-
nation and incorporating novel biomarkers can improve the prac-
tical evaluation of novel–novel combination therapies. However, 
biomarker- driven clinical trials using combination therapies pres-
ent additional challenges and require careful consideration of the 
biomarkers’ performance and clinical utility.
7. Actionability of oncogenic driver mutations and utility of a specific 
biomarker in one cancer type does not predict similar outcomes 
in other cancers, for example, EGFR in NSCLC versus CRC, TMB in 
NSCLC versus gliomas. Therefore, preclinical and clinical rationales 
for biomarker- driven combination therapies in one cancer cannot 
justify a combination trial in another histology.
8. There were no prior activity data for monotherapy in specific tumor 
cohorts in many basket trials (eg, MyPathway and ROAR).
9. Garnering regulatory approval requires demonstrating that 
each component of a combination contributes to its benefit. 
Such demonstrations may entail factorial designs and require 
interacting closely with regulators.
10. Partial factorial designs in adaptive clinical trials are likely to 
be the best and most efficient solutions for the future, espe-
cially in the context of precision medicine where biomarker- 
defined subpopulations are becoming the norm.
B. Recommendations
1. Avoid duplication in partner targets in unselected patients, par-




2. In the design of a combination, consider whether other monotherapy 
arms are required when trial designs are conceived.
3. Consider if randomized arms of monotherapy are ethical; for ex-
ample, if based on the mechanism of action, no clinical activity of 
monotherapy is expected.
4. Consider use of milestone survival or response endpoints to more 
efficiently generate early evidence.
5. Consider the incorporation of real- world evidence and novel hybrid 
designs, including in regulatory decision making.
6. Consider using (historical) data on single- agent efficacy, ideally to 
be obtained from multiple datasets and for all agents within the 
combination.
7. Consider introducing experimental therapies, including novel–novel 
combinations, into the trial at any time, allowing for rational combi-
nations based on new biological or clinical insights.
8. Consider innovative but sound statistical methods, including 
use of historical or external data sources to support combination 
approaches.
CRC, colorectal cancer; EGFR, epidermal growth factor receptor; NSCLC, non- 
small cell lung cancer; TMB, tumor mutational burden.
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the various elements among patients. Therefore, without 
relevant biomarker selection- driven trial design, clinical 
efficacy may not be gleaned with an all- comers approach.
Trial design with appropriate comparator arms of mono-
therapy was also assessed for each trial. Most studies (66%) 
were considered to have appropriate comparator arms 
or had supportive external data sources such as prior 
studies of monotherapy. Noticeably, in basket trials, such 
as MyPathway54 55 and ROAR (Rare Oncology Agnostic 
Research),82 there were no data for monotherapy in certain 
tumor cohorts. However, basket trials in rare tumor types 
or uncommon molecular subsets clearly face practical 
challenges in terms of statistical design and patient recruit-
ment. This emphasizes the need for a comprehensive 
understanding of tumor biology to identify optimal combi-
nations.83 There is also increasing use and acceptance of 
real- world evidence in regulatory decision making.84 Histor-
ical data on single- agent efficacy would ideally come from 
multiple datasets and for all agents within the combina-
tion.85 There may also be situations in which randomized 
arms of monotherapy may be unethical, for example, if 
no clinical activity of monotherapy is expected based on 
the mechanism of action. This heightens the importance 
of careful consideration to determine whether additional 
arms of monotherapy are required when trial designs are 
conceived.
Finally, all studies were evaluated as selecting a primary 
endpoint, which demonstrated a clinically meaningful 
benefit. Nonetheless, there can be complexities in deter-
mining the validity of surrogate endpoints particularly for 
early- phase combination immunotherapy trials. Milestone 
survival or response endpoints are increasingly used86 to 
more efficiently generate early evidence. KEYNOTE-14687 
for example, had a primary endpoint of ORR at 24 weeks, 
and ultimately was the basis of FDA approval for the combi-
nation of pembrolizumab plus lenvatinib in endometrial 
cancer.88 This trial also provides important insights into 
the use of historical data to evaluate the treatment effect 
of lenvatinib and pembrolizumab monotherapy.89 90 Addi-
tional exploratory post hoc analyses using propensity score 
approaches were also conducted by the FDA to evaluate the 
contribution of each agent.88 Importantly though, confir-
matory randomized trials evaluating the combination are 
still ongoing.
Collectively, our review has identified that improvements 
in the effective evaluation of novel–novel combination ther-
apies are clearly needed. Many of these findings may also 
be applicable to other combination therapies, including a 
new combination of two previously approved agents or the 
addition of a new agent to an existing approved therapy. 
In box 1, we provide a series of recommendations on the 
efficient design of future clinical trials evaluating novel 
combination therapies. Novel adaptive trial designs repre-
sent one approach that may enhance the efficiency of 
trials. GBM AGILE, a phase II/III adaptive platform trial 
(NCT03970447), is an example which incorporates statistical 
innovations such as Bayesian Adaptive design in a seamless 
registration trial.91 Candidate biomarkers may be identified 
and validated under this single platform master protocol. 
Furthermore, experimental therapies, including novel–
novel combinations, may be introduced into the trial at any 
time, allowing for rational combinations based on advances 
in our biological understanding of tumors. Pharmaceutical 
platforms are also increasingly using multiarm random-
ized trials, for example, MORPHEUS (NCT03193190, 
NCT03281369, NCT03280563, NCT03424005, and 
NCT03337698), with multiple combination therapy arms 
compared against a single standard- of- care control arm, 
and allow for the introduction of novel–novel combina-
tions at any time.92 Additionally, seamless phase I/II trials 
are becoming more commonly used93 and highlight that 
many of the considerations we have outlined previously 
may become increasingly important in the strategic design 
of early- phase studies as well. In particular, this includes the 
introduction of experimental rational combinations based 
on emerging biological or clinical insights—to establish 
appropriate dosing and characterize safety.
There are several limitations to our review, including the 
restricted time period (July 2017–June 2020) and journal 
selection, which may have introduced inherent publication 
bias into the studies included in our review. However, there 
were still 6/32 (19%) trials, which did not meet the primary 
endpoint included, and our evaluation criteria were not 
dependent on the trial’s primary outcome. In selecting only 
published trials, which was required to assess our evaluation 
criteria, contemporary trials such as the aforementioned 
adaptive platform trials will have been excluded. Broader 
evaluation of ongoing and unpublished trials is therefore 
also warranted, although outside the scope of this study. 
The included trials also represent the data known at the 
time of initial publication, not necessarily the data known at 
the time of trial design, and may therefore not completely 
reveal the historical sequence of events at the time of 
study conception. Ultimately though, there also needs to 
be inherent flexibility to adapt to rapidly evolving clinical 
paradigms. Lastly, there is significant heterogeneity of the 
included trials, particularly with regard to tumor types, trial 
design and mechanism of action of drug combinations. 
Nevertheless, the primary focus of this review was to identify 
guiding principles to improve trial efficiency in evaluating 
novel–novel drug combinations. Our analysis provided key 
insights into the published literature with recommenda-
tions (box 1) to improve paradigms for drug development 
and future trial design.
CONCLUSIONS
Designing trials to evaluate novel–novel combination 
therapies presents numerous challenges to demon-
strate efficacy in a comprehensive manner. Critically, 
a greater understanding of the biological rationale for 
the combination and incorporating novel predictive 
biomarkers may further improve the effective evalua-
tion of novel–novel combination therapies. Innovative 
statistical methods and increasing the use of histor-
ical or external data sources to support combination 
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approaches are potential strategies that may improve 
the efficiency of trial design.
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